Perez Martinez, Antonio - Portal de Investigación del Consorcio Madroño

Herrera L, Martin-Inaraja M, Santos S, Inglés-Ferrándiz M, Azkarate A, Perez-Vaquero MA, Vesga MA, Vicario JL, Soria B, Solano C, De Paz R, Marcos A, Ferreras C, Perez-Martinez A, Eguizabal C

Immunology (p. 234-249) - 1/2/2022

10.1111/imm.13432

ISSN 13652567

iMarina

Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH)

González Vicent M, Díaz de Heredia C, González de Pablo J, Molina B, Regueiro A, Pérez Martinez A, Palomo P, López Corral L, García E, Fernández JM, Pérez A, Jiménez MJ, Guerreiro M, Vallejo C, Gallardo AI, López O, Benito A, Marsal J, Duarte M, Bento L, Badell I, Pedraza A, Jiménez Ubieto A, González P, Gómez Centurión I, Costilla L, Beléndez C, Esquirol A, Espigado I, Lavilla E, Díaz MÁ

European Journal Of Haematology (p. 842-850) - 1/6/2021

10.1111/ejh.13618

ISSN 16000609

iMarina

Este/a investigador/a no tiene proyectos de investigación.

Análisis comparativo de los resultados del trasplante de sangre de cordón umbilical y haploidéntico en pacientes pediátricos con hemopatías malignas

Figuera Alvarez, Angela (Autor o Coautor)
Antonio Pérez Martínez (Director)
Perez Martinez, Antonio (Autor o Coautor)
M (Director) Doctorando: C. Gómez Santos

1/1/2017

iMarina

Evaluation of NKG2D chimeric antigen receptor redirected CD45RA- T cells as treatment for pediatric acute leukemia

Fernández Casanova, Lucía (Director)
Perez Martinez, Antonio (Director) Doctorando: Fernández Martínez, Adrián

20/5/2022

iMarina

Inmunoterapia en sarcomas pediátricos: Combinación de la terapia con células Natural Killer activadas y expandidas, y el anticuerpo anti-CXCR4 MDX1338

Perez Martinez, Antonio (Director)
Vela Cuenca, María (Director) Doctorando: Bueno Sánchez, David

7/6/2019

iMarina

Producción de células natural KILLER activadas con Interleuquina-15 para uso clínico en pacientes pediátricos con cáncer

Antonio Pérez Martínez (Director)
Perez Martinez, Antonio (Autor o Coautor) Doctorando: María Dolores Corral Sánchez

22/10/2018

iMarina

Patrón de recaída postrasplante hematopoyético en pacientes pediátricos con hemopatías malignas. Evaluación del efecto aloinmune

Miguel Ángel Díaz Pérez (Director)
Antonio Pérez Martínez (Director)
Perez Martinez, Antonio (Autor o Coautor) Doctorando: Blanca Molina Angulo

18/9/2017

iMarina

Papel de las células natural killer en la leucemia infantil en situación de identidad HLA

M (Director)
Antonio Pérez Martínez (Director)
Perez Martinez, Antonio (Autor o Coautor) Doctorando: Isabel Martínez Romera

22/7/2016

iMarina

Este/a investigador/a no tiene patentes o licencias de software.

Perfiles de investigador/a

ORCID
- 0000-0002-6436-9195
Scopus Author ID
- 7006230880
Dialnet id
- 3249192

Última actualización de los datos: 18/03/24 22:10

Perez Martinez, Antonio antonio.perez@uam.es

Actividades

Influence of a Moderate-Intensity Exercise Program on Early NK Cell Immune Recovery in Pediatric Patients After Reduced-Intensity Hematopoietic Stem Cell Transplantation

Familial CD45RA– T cells to treat severe refractory infections in immunocompromised patients

Pets for pediatric transplant recipients: To have or not to have

Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment

In vitro Natural Killer Cell Immunotherapy for Medulloblastoma

Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy

Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells

CLINICAL GRADE ACTIVATED NATURAL KILLER PRODUCTS FOR ADOPTIVE IMMUNOTHERAPY AGAINST HIGH-RISK MALIGNANCIES

A PHASE I/II DOSE-ESCALATION SINGLE CENTER STUDY TO EVALUATE THE SAFETY OF INFUSION OF MEMORY T CELLS AS ADOPTIVE THERAPY IN CORONAVIRUS PNEUMONIA AND /OR LYMPHOPENIA (RELEASE)

A Phase I Dose-Escalation Single Center Study To Evaluate The Safety Of Allogenic Memory T Cells Containing SARS-COV-2 Specific Lymphocytes As Adoptive Therapy in COVID19

Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: A prospective evaluation of risk factors and outcome

KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors

Ataxia-telangiectasia and wilms tumor: reduced treatment but early relapse

Spontaneous resolution of hypereosinophilic syndrome in an infant without treatment

[Benign intracranial hypertension and heterozygosity for factor V Leiden mutation]

Exercise during hematopoietic stem cell transplant hospitalization in children

Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors

High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors

Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for adoptive cell therapy